TORONTO, ONTARIO — (Marketwired) — 02/06/17 — Abattis Bioceuticals Corp. is in default of CSE requirements. Effective immediately, Abattis Bioceuticals will be suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules. A cease trade order has been issued by the British Columbia Securities Commission and the Ontario Securities Commission.
Date: Effective immediately, February 6, 2017
Symbol: ATT
Contacts:
Canadian Securities Exchange (CSE)
Listings
(416) 367-7340